- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory mantle cell lymphoma (R/R MCL)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1636KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 207KB)
Acalabrutinib – July 2021
Acalabrutinib: Capsule 100 mg; Calquence®
Last updated
29 October 2021